MARKER THERAPEUTICS, INC. Operating Lease Cost
MARKER THERAPEUTICS, INC. (MRKR) reported Operating Lease Cost of $258.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2023-05-15
- MARKER THERAPEUTICS, INC. operating lease, cost for the quarter ending 2023-03-31 was $258.00K, a 39.29% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, cost for the quarter ending 2022-12-31 was $258.00K, a 39.58% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, cost for the quarter ending 2022-09-30 was $375.00K, a 11.76% decline year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, cost for the quarter ending 2022-06-30 was $425.00K, a 0.00% change year-over-year.
- MARKER THERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $1.48M, a 12.87% decline from fiscal 2021.
- MARKER THERAPEUTICS, INC. operating lease, cost for fiscal 2021 was $1.70M, a 77.29% increase from fiscal 2020.
- MARKER THERAPEUTICS, INC. operating lease, cost for fiscal 2020 was $960.00K, a 336.36% increase from fiscal 2019.
- MARKER THERAPEUTICS, INC. operating lease, cost for fiscal 2019 was $220.00K, a 25.28% increase from fiscal 2018.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $258.00K 10-Q · filed 2023-05-15 | $516.00K derived: sum of 2 quarters · filed 2023-05-15 | $891.00K derived: sum of 3 quarters · filed 2023-05-15 | $1.32M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $633.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.06M derived: sum of 3 quarters · filed 2023-03-22 | $1.48M 10-K · filed 2023-03-22 |
| 2022-09-30 | $375.00K 10-Q · filed 2022-11-10 | $800.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.23M 10-Q · filed 2022-11-10 | $1.65M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-06-30 | $425.00K 10-Q · filed 2022-08-11 | $850.00K 10-Q · filed 2022-08-11 | $1.28M derived: sum of 3 quarters · filed 2023-05-15 | $1.70M derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-03-31 | $425.00K 10-Q · filed 2023-05-15 | $852.00K derived: sum of 2 quarters · filed 2023-05-15 | $1.28M derived: sum of 3 quarters · filed 2023-05-15 | $1.70M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $852.00K derived: sum of 2 quarters · filed 2023-03-22 | $1.28M derived: sum of 3 quarters · filed 2023-03-22 | $1.70M 10-K · filed 2023-03-22 |
| 2021-09-30 | $425.00K 10-Q · filed 2022-11-10 | $850.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.27M 10-Q · filed 2022-11-10 | $1.70M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $425.00K 10-Q · filed 2022-08-11 | $850.00K 10-Q · filed 2022-08-11 | $1.28M derived: sum of 3 quarters · filed 2022-08-11 | $1.65M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $425.00K 10-Q · filed 2022-05-13 | $852.00K derived: sum of 2 quarters · filed 2022-05-13 | $1.23M derived: sum of 3 quarters · filed 2022-05-13 | $1.33M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $427.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $802.00K derived: sum of 2 quarters · filed 2022-03-17 | $905.00K derived: sum of 3 quarters · filed 2022-03-17 | $960.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $375.00K 10-Q · filed 2021-11-10 | $478.00K derived: sum of 2 quarters · filed 2021-11-10 | $533.00K 10-Q · filed 2021-11-10 | $588.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $103.00K 10-Q · filed 2021-08-10 | $158.00K 10-Q · filed 2021-08-10 | $213.00K derived: sum of 3 quarters · filed 2021-08-10 | $268.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $55.00K 10-Q · filed 2021-05-12 | $110.00K derived: sum of 2 quarters · filed 2021-05-12 | $165.00K derived: sum of 3 quarters · filed 2021-05-12 | $220.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $110.00K derived: sum of 2 quarters · filed 2021-03-09 | $165.00K derived: sum of 3 quarters · filed 2021-03-09 | $220.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $55.00K 10-Q · filed 2020-11-09 | $110.00K derived: sum of 2 quarters · filed 2020-11-09 | $165.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $55.00K 10-Q · filed 2020-08-10 | $110.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $55.00K 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | $175.60K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |